Oxford Biomedica signs supply deal with Axovant Gene Therapies
(Sharecast News) - Gene and cell therapy company Oxford Biomedica has signed a three-year clinical supply agreement with a wholly-owned subsidiary of Axovant Gene Therapies, it announced on Friday.
Read more